Fluoroquinolone efflux mediated by ABC transporters

Journal of Pharmaceutical Sciences

Volumn 97, Issue 9, 2008, Pages 3483-3493

  Alvarez, Ana I ^a   Pérez, Miriam ^a   Prieto, Julio G ^a   Molina, Antonio J ^a   Real, Rebeca ^a   Merino, Gracia ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

ABC transporters; BCRP ABCG2; Drug resistance; Efflux pumps; Fluoroquinolones; Mammary transport; P glycoprotein; Pharmacokinetics

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CIMETIDINE; CIPROFLOXACIN; CYCLOSPORIN A; DANOFLOXACIN; ENROFLOXACIN; ERYTHROMYCIN; GLYCOPROTEIN P; GREPAFLOXACIN; LEVOFLOXACIN; MESYLIC ACID; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NORFLOXACIN; OFLOXACIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; VINCRISTINE;

ANTIBIOTIC RESISTANCE; BIOAVAILABILITY; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INHIBITION; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; INTESTINE SECRETION; LACTATION; NEUROTOXICITY; NONHUMAN; PROTEIN SECRETION; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

EID: 42949154087     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21233     Document Type: Article

References (78)

1. Ball P. 2000. Quinolone generations: Natural history or natural selection. J Antimicrob Chemother 46:17-24.
2. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. 2005. Quinolones in 2005: An update. Clin Microbiol Infect 11:256-280.
3. Hooper DC. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7:337-341.
4. Van Bambeke F, Glupczynski Y, Plésiat P, Pechère JC, Tulkens PM. 2003. Antibiotic efflux pumps in prokaryotic cells: Occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 51:1055-1065.
5. Van Bambeke F, Michot JM, Tulkens PM. 2003. Antibiotic efflux pumps in eukaryotic cells: Occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother 51:1067-1077.
6. Appelbaum PC, Hunter PA. 2000. The fluoroquinolone antibacterials: Past, present and future perspectives. Int J Antimicrob Agents 16:5-15.
7. Martinez M, McDermott P, Walker R. 2006. Pharmacology of the fluoroquinolones: A perspective for the use in domestic animals. Vet J 172: 10-28.
8. Goss WA, Deitz WH, Cook TM. 1965. Mechanism of action of nalidixic acid on Escherichia coli. J Bacteriol 89:1068-1074.
9. Crumplin GC, Midgley JM, Smith JT. 1980. Mechanism of action of nalidixic acid and its congeners. Top Antibiot Chem 3:9-38.
10. Von Rosenstiel N, Adam D. 1994. Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs 47:872-890.
11. Peterson LR. 2001. Quinolone molecular structure-activity relationships: What we have learned about improving antimicrobial activity. Clin Infect Dis 33: S180-S186.
12. Georgopapadakou N, Dix B, Angehrn P, Wick A, Olson G. 1987. Monocyclic and tricyclic analogs of quinolones: Mechanism of action. J Antimicrob Chemother 31:614-616.
13. Maxwell A. 1992. The molecular basis of quinolone action. J Antimicrob Chemother 30:409-414.
14. Willmott CJ, Critchlow SE, Eperon IC, Maxwell A. 1994. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol 242:351-363.
15. Drlica K, Zhao X. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol 61:377-392.
16. Chen AY, Liu LF. 1994. DNA topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191-218.
17. Blondeau JM. 2004. Fluoroquinolones: Mechanism of action, classification, and development of resistance. Surv Ophthalmol 49:S73-S78.
18. Lamp KC, Bailey EM, Rybak MJ. 1992. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 22: 32-46.
19. Sörgel F, Jaehde U, Naber KG, Stephan U. 1989. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet 16:51S-68S.
20. Rohwedder RW, Bergan T, Thorsteinsson SB, Scholl H. 1990. Transintestinal elimination of ciprofloxacin. Diagn Microbiol Infect Dis 13:127-133.
21. Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R. 1996. Intestinal elimination of ofloxacin enantiomers in the rat: Evidence of a carrier-mediated process. Antimicrob Agents Chemother 36:2506-2511.
22. Cao CX, Silverstein SC, Neu C, Steinberg TH. 1992. J774 macrophages secrete antibiotics via organic anion transporters. J Infect Dis 165:322-328.
23. Griffiths NM, Hirst BH, Simmons NL. 1993. Active secretion of the fluoroquinolone ciprofloxacin by human intestinal epithelial Caco-2 cell layers. Br J Pharmacol 108:575-576.
24. Griffiths NM, Hirst BH, Simmons NL. 1994. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and Pefloxacin; a common secretory pathway. J Pharmacol Exp Ther 269:496-502.
25. Dean M, Allikmets R. 2001. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33:475-479.
26. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliver Rev 55:3-29.
27. Ejendal KFK, Hrycyna CA. 2002. Multidrug resistance and cancer: The role of the human ABC transporter AB CG2. Curr Protein Pept Sci 3: 503-511.
28. Varma MVS, Ashokraj Y, Dey CS, Pachagnula R. 2003. P-Glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res 48:347-359.
29. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. 2004. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1: 27-42.
30. Leslie EM, Deeley RG, Cole SP. 2005. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
31. Shitara Y, Horie T, Sugiyama Y. 2006. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
32. Cormet-Boyaka E, Huneau JF, Mordrelle A, Boyaka PN, Carbon C, Rubinstein E, Tome D. 1998. Secretion of Sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Antimicrob Agents Chemother 42:2607-2611.
33. Matsuo Y, Yano I, Ito T, Hashimoto Y, Inui K. 1998. Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC- PK1. J Pharmacol Exp Ther 287:672-678.
34. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. 2006. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
35. Yamaguchi H, Yano I, Saito H, Inui KI. 2002. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 300:1063-1069.
36. Sikri V, Pal D, Jain R, Kalyani D, Mitra AK. 2004. Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. Am J Ther 11:433-442.
37. Sasaya M, Hatakeyama Y, Saitoh H, Takada M. 1999. Stereoselective permeation of new fluorinated quinolone derivatives across LLC-PK1 cell monolayers. Biol Pharm Bull 22:707-712.
38. Evans WE, McLeod HL. 2003. Pharmacogenomics and drug disposition, drug targets, and side effects. N Engl J Med 348:538-549.
39. Smith N, Figg WD, Sparreboom A. 2004. Recent advances in pharmacogenetic approaches to anticancer drug development. Drug Dev Res 62:233-253.
40. Dean M. 2005. The genetics of ATP-binding cassette transporters. Methods Enzymol 400:409-429.
41. Hooper DC. 2002. Fluoroquinolone resistance among Grampositive cocci. Lancet Infect Dis 2: 530-538.
42. Drlica K, Malik M. 2003. Fluoroquinolones: Action and resistance: Current topics in medical chemistry 3:249-282.
43. Yamaguchi H, Yano I, Saito H, Inui KI. 2004. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rat. Pharm Res 21:330-338.
44. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ. 2002. A critical review of the fluoroquinolones: Focus on respiratory infections. Drugs 62:13-59.
45. Schrickx JA, Fink-Gremmels J. 2007. Danoflox-acin-mesylate is a substrate for ATP-dependent efflux transporters. Br J Pharmacol 150:463-469.
46. Pulido MM, Molina AJ, Merino G, Mendoza G, Prieto JG, Alvarez AI. 2006. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): Influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther 29:279-287.
47. Cavet ME, West M, Simmons NL. 1997. Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 121:1567-1578.
48. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R. 1999. Active intestinal elimination of ciprofloxacin in rats: Modulation by different substrates. Br J Pharmacol 127:1728-1734.
49. Lowes S, Simmons NL. 2002. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 135:1263-1275.
50. Yamaguchi H, Yano I, Hashimoto Y, Inui KI. 2000. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. J Pharmacol Exp Ther 295:360-366.
51. Yamaguchi H, Yano I, Saito H, Inui KI. 2001. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. Eur J Pharmacol 431:297-303.
52. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A. 2002. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother 46:344-349.
53. Xia CQ, Liu N, Yang D, Miwa G, Gan LS. 2005. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 33:637-643.
54. Fernandez-Teruel C, Gonzalez-Alvarez I, Casabo VG, Ruiz-Garcia A, Bermejo M. 2005. Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells. J Drug Target 13:199-212.
55. Sasabe H, Terasaki T, Tsuji A, Sugiyama Y. 1997. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. J Pharmacol Exp Ther 282:162-171.
56. Sasabe H, Tsuji A, Sugiyama Y. 1998. Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther 284:1033-1039.
57. Sasabe H, Kato Y, Tsuji A, Sugiyama Y. 1998. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. J Pharmacol Exp Ther 284:661-668.
58. Zhao YL, Cai SH, Wang L, Kitaichi K, Tatsumi Y, Nadai M, Yoshizumi H, Takagi K, Takagi K, Hasegawa T. 2002. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxaein. Clin Exp Pharmacol Physiol 29:167-172.
59. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. 2004. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxaein in mice. J Pharmacol Exp Ther 310:648-655.
60. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S. 2000. Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother 44:1697-1700.
61. Ando T, Kusuhara H, Merino G, Alvarez AI, Schinkel AH, Sugiyama Y. 2007. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos 35:1873-1879.
62. Foote EF, Halstenson CE. 1998. Effects of probenecid and Cimetidine on renal disposition of ofloxacin in rats. Antimicrob Agents Chemother 42:456-458.
63. Ito T, Yano I, Masuda S, Hashimoto Y, Inui K. 1999. Distribution characteristics of levofloxacin and grepafloxaein in rat kidney. Pharm Res 16: 534-539.
64. Ito T, Yano I, Hashimoto Y, Inui K. 2000. Transepithelial transport of levofloxacin in the isolated perfused rat kidney. Pharm Res 17:236-241.
65. Ito T,Yano I.Tanaka K,Inui K. 1997. Transport of quinolone antibacterial drugs by human P-Glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther 282:955-960.
66. Sasaya M, Oda M, Endo T, Saitoh H, Takada M. 1997. The transport of ciprofloxacin in cultured kidney epithelial cells LLC-PK1. Biol Pharm Bull 20:887-891.
67. Tamai I, Yamashita J, Kido Y, Ohnari A, Sai Y, Shima Y, Naruhashi K, Koizumi S, Tsuji A. 2000. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther 295:146-152.
68. Ooie T, Suzuki H, Terasaki T, Sugiyama Y. 1997. Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system. Drug Metab Disp 25:784-789.
69. Ooie T, Suzuki H, Terasaki T, Sugiyama Y. 1997. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J Pharmacol Exp Ther 283:293-304.
70. Delon A, Pariat C, Courtois P, Bouquet S, Couet W. 1998. A new approach for early assessment of the epileptogenic potential of quinolones. Antimicrob Agents Chemother 42:2756-27585.
71. Lange EC, Marchand S, van den Berg D, van der Sandt IC, de Boer AG, Delon A, Bouquet S, Couet W. 2000. In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of Sparfloxacin. Eur J Pharm Sci 12:85-93.
72. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. 2004. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301.
73. Jonker JW, Merino G, Musters S, Van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH. 2005. The breast cancer resistance protein BCRP (ABCG2) concentrates drug and carcinogenic xenotoxins into milk. Nat Med 11: 127-129.
74. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. 2005. Carrier-mediated uptake of grepafloxaein, a fluoroquinolone antibiotic, by the isolated rat lung cells. Drug Metab Pharmacokinet 20:491-495.
75. Haritova AM, Schrickx JA, Fink-Gremmels J. 2007. Functional studies on the activity of efflux transporters in an ex vivo model with chicken splenocytes and evaluation of selected fluoroquinolones in this model. Biochem Pharmacol 73:752-759.
76. Seral C, Carryn S, Tulkens PM, Van Bambeke F. 2003. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother 51:1167-1173.
77. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2005. Related articles, influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 49: 2429-2437.
78. Michot JM, Heremans MF, Caceres NE, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2006. Cellular accumulation and activity of quinolones in ciprofloxacin-resistant J774 macrophages. Antimicrob Agents Chemother 50:1689-1695.